{"filing":{"accession_number":"0001193125-26-253436","cik":"0001419041","ticker":"FBRX","company_name":"Forte Biosciences, Inc.","form":"8-K","filing_date":"2026-06-02","report_date":null,"primary_document":"d110060d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1419041/000119312526253436/d110060d8k.htm"},"events":[{"id":7459,"run_id":6555,"accession_number":"0001193125-26-253436","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Forte Biosciences held its 2026 annual meeting of stockholders on May 29, 2026, with shareholders voting on four matters: election of Class III directors (Kornfeld, Brun, Wagner), ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and approval of the Amended and Restated 2021 Equity Incentive Plan. All proposals passed with substantial majorities.","company_name":"Forte Biosciences, Inc.","ticker":"FBRX","filing_date":"2026-06-02","form":"8-K","submitted_at":null,"items":[{"id":3570,"accession_number":"0001193125-26-253436","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amended and restated equity incentive plan that governs compensatory arrangements for employees, directors, and consultants. The filing details the plan's purposes (attracting and retaining personnel through equity grants), the share reserve increase (5,190,000 newly reserved shares), and references the proxy statement describing material terms. This is a classic exec_compensation event under Item 5.02(e), distinct from executive departures or appointments.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:17:01.810465+00:00","company_name":"","ticker":null,"filing_date":""},{"id":3571,"accession_number":"0001193125-26-253436","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from Forte Biosciences' 2026 annual meeting held May 29, 2026. The filing reports voting outcomes on four matters: election of Class III directors (Kornfeld, Brun, Wagner), ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and approval of the Amended and Restated 2021 Equity Incentive Plan. All proposals passed with substantial majorities, making this a material disclosure of governance and compensation decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:17:01.810465+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3570,"accession_number":"0001193125-26-253436","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amended and restated equity incentive plan that governs compensatory arrangements for employees, directors, and consultants. The filing details the plan's purposes (attracting and retaining personnel through equity grants), the share reserve increase (5,190,000 newly reserved shares), and references the proxy statement describing material terms. This is a classic exec_compensation event under Item 5.02(e), distinct from executive departures or appointments.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:17:01.810465+00:00","company_name":"Forte Biosciences, Inc.","ticker":"FBRX","filing_date":"2026-06-02"},{"id":3571,"accession_number":"0001193125-26-253436","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from Forte Biosciences' 2026 annual meeting held May 29, 2026. The filing reports voting outcomes on four matters: election of Class III directors (Kornfeld, Brun, Wagner), ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and approval of the Amended and Restated 2021 Equity Incentive Plan. All proposals passed with substantial majorities, making this a material disclosure of governance and compensation decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:17:01.810465+00:00","company_name":"Forte Biosciences, Inc.","ticker":"FBRX","filing_date":"2026-06-02"}]}